Prophylactic and preemptive therapy with dasatinib after hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia.

[1]  H. Kantarjian,et al.  Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[2]  R. Foà,et al.  Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. , 2011, Blood.

[3]  H. Kantarjian,et al.  Role of Tyrosine Kinase Inhibitors in the Management of Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia , 2011, Current hematologic malignancy reports.

[4]  M. Wetzler,et al.  Philadelphia chromosome‐positive acute lymphoblastic leukemia , 2011, Cancer.

[5]  H. Kantarjian,et al.  First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. , 2010, Blood.

[6]  J. Esteve,et al.  Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial , 2010, Haematologica.

[7]  R. Foà,et al.  Gruppo Italiano Malattie Ematologiche dell ' Adulto ( GIMEMA ) acute lymphoblastic leukemia without additional chemotherapy : results survival in elderly Philadelphia chromosome – positive patients with Imatinib plus steroids induces complete remissions and prolonged , 2007 .

[8]  M. Sattler,et al.  Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML). , 2006, Critical reviews in oncology/hematology.

[9]  Je-Hwan Lee,et al.  Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia , 2005, Leukemia.

[10]  G. Ledderose,et al.  Ph Philadelphia-positive acute lymphoblastic leukemia + outcome in MRD Early molecular response to posttransplantation imatinib determines , 2005 .

[11]  J. Mestan,et al.  In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. , 2005, Cancer research.

[12]  R. Champlin,et al.  Re: Imatinib mesylate administration in the first 100 days after stem cell transplantation. , 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.